Search clinical trials for: REGN3470-3471-3479

Total 1081 results

Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | Clinical... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Carcinoma, Renal Cell

Poland, Australia, Japan, United States, Korea, Republic of, Taiwan, China, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Romani... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Recurrent Pancreatic Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Metastatic Malignant Neoplasm in the Bone | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Malignant Solid Neoplasm | Head and Neck Squamous Cell Carcinoma

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Renal Cell Carcinoma

United States
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of a Single Dose of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Healthy | Renal Dysfunction

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
MedSIR
Merck Sharp & Dohme LLC

Active, not recruiting

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)

Metastatic Thymic Carcinoma | Thymoma Type B3

Spain, France, Italy
Gulam Manji
Merck Sharp & Dohme LLC

Completed

Perioperative Chemo and Pembrolizumab in Gastric Cancer

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Withdrawn

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA... and other conditions

United States
Roswell Park Cancer Institute

Not yet recruiting

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Recurrent Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; National...

Active, not recruiting

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...

Active, not recruiting

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Schizophrenia
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Melanoma
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Biliary Tract Carcinoma

China
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | ALK Gene Mutation | EGFR Gene Mutation | Metastatic Head and Neck... and other conditions

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes... and other collaborators

Completed

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditions

United States
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Advanced Hepatocellular Carcinoma

United States, China, Italy, Japan, Korea, Republic of, Poland, Spain, Switzerland, Taiwan
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Unknown

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage III Breast Cancer

United States
Samsung Medical Center

Unknown

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

Stage IIIA Non-small Cell Lung Cancer

Korea, Republic of
Dart NeuroScience, LLC

Terminated

DNS-3379 vs. Placebo in Stroke Rehabilitation (SPIRIT)

Ischemic Stroke

Australia, New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Multiple Doses of Danicopan in Healthy Participants

Healthy

New Zealand
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, Switzerland, South Africa, Denmark, Argentina, Colombia
Fujifilm Pharmaceuticals U.S.A., Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors

Advanced Solid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Non-Small Cell Lung Cancer

Poland, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukr... and more
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Urothelial Carcinoma Associated 1 RNA, Human
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)-China Extension Study

Head and Neck Squamous Cell Carcinoma

China
Medical Research Council
Merck Sharp & Dohme LLC; Aarhus University Hospital; NCRI Clinical Studies Groups and other collaborators

Unknown

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Glioblastoma

United States, Italy, Belgium, Germany, Poland, Russian Federation, Spain, Switzerland, Ukraine, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (ZENITH)

Schizophrenia

Korea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC; Merck Serono GmbH, Germany

Recruiting

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT)

Non Small Cell Lung Cancer | Advanced Cancer

United Kingdom
Presage Biosciences
Merck Sharp & Dohme LLC

Completed

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Soft Tissue Sarcoma | Head and Neck Squamous Cell Carcinoma

United States
NYU Langone Health

Active, not recruiting

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Malignant Melanoma

China
Celgene

Active, not recruiting

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Italy, France, Germany, Greece, Spain

Search clinical trials for: REGN3470-3471-3479

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations